Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Cindy Devone-Pacheco

Results from Many Large Clinical Trials Remain Unpublished Years Later

Will Boggs MD  |  May 9, 2019

NEW YORK (Reuters Health)—Results from a substantial proportion of large, registered, randomized controlled trials (RCTs) can go unpublished for years after their completion, researchers report. “These unpublished and unreported trials include a vast number of patients, about 90,000,” Dr. John P. A. Ioannidis from Stanford University in California told Reuters Health. “Many people think that…

Osteoporotic Fracture Rates Similar with Denosumab, Alendronate in Real World

Megan Brooks  |  April 25, 2019

NEW YORK (Reuters Health)—Rates of osteoporotic fracture were similar three years after starting either denosumab or alendronate in a real-world Danish population-based cohort study. “Previous studies have shown that denosumab is more efficacious than alendronate in increasing bone mineral density (BMD), possibly the best proxy outcome for subsequent fracture risk. However, previous studies were underpowered…

Parent-Child Reminiscing Affects Children’s Pain Memories

Reuters Staff  |  April 22, 2019

NEW YORK (Reuters Health)—How parents and children reminisce about the child’s recent surgery affects the child’s pain memory, researchers from Canada report. Children who recall pain that is higher than initially reported are more likely to report more pain and distress during future pain experiences. These negatively biased memories, formed early in life, set the…

IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results

Will Boggs MD  |  April 22, 2019

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) can safely switch from infliximab to the biosimilar CT-P13, though they may face a higher risk of clinical relapse, researchers from Spain report. Recent studies have demonstrated the effectiveness and safety of infliximab biosimilars in patients with IBD, but there are limited data about the effectiveness…

Advocacy Begins at Home

Chris Morris, MD  |  April 3, 2019

As the frustration with changes in healthcare grows, and after speaking with the vociferous advocates who are part of the ACR, you have decided that you need to become involved in advocacy for your patients, your practice and your profession. Welcome to the fold. How to Help from Home Many people indicate they aren’t more…

Kentucky Launches Probe into Drug Overcharges by Pharmacy Benefit Managers

Reuters Staff  |  March 25, 2019

(Reuters)—Kentucky Attorney General Andy Beshear said on Thursday he had launched an investigation into allegations that pharmacy benefit managers (PBMs) had overcharged state health insurance programs for drugs and discriminated against independent pharmacies. The investigation comes against the backdrop of widespread criticism of rising costs of prescription medicines in the United States, with PBMs, middlemen…

The RISE Registry: A Powerful Collaboration Tool for Clinicians & Researchers

Nancy A. Baker, SCD, MPH, OT; Margarita Fallena, MD; Tracy Johansson, MS; Janell Martin, CAE; Kaleb Michaud, PhD; Cynthia S. Crowson, PhD; Dina L. Jones, PT, PhD  |  March 21, 2019

Practice-based evidence, like that in the RISE registry, can be used to describe trends in patient care, look at comparative effectiveness of interventions and much more.

Democrats Support Expanding Medicare, with Some Caveats that Could Matter to Voters

Amanda Becker and Ginger Gibson  |  March 14, 2019

WASHINGTON/ST. GEORGE, S.C.—After launching his 2020 presidential bid last week, John Hickenlooper took a different stance on establishing a “Medicare-for-all” government health insurance program than many of his Democratic competitors. “I probably would oppose Medicare-for-all just because there are over 150 million people, Americans who have some form of private insurance through their business, and…

Why Fellows Should Care about Advocacy

Blaine Lapin, MD  |  March 5, 2019

As a physician, I am an advocate. I am an advocate for my patients individually and collectively, and I am an advocate for my field: pediatric rheumatology. My own experiences as a patient drive me to integrate my patients’ perspectives into my medical decision making, and although my academic training has prepared me to best…

CMS Says U.S. Health Spending to Rise 5.5% Per Year over Next Decade

Tamara Mathias and Saumya Joseph  |  February 20, 2019

(Reuters)—U.S. health spending is expected to grow at an average rate of 5.5% every year from 2018 over the next decade and will reach nearly $6 trillion by 2027 as more people become eligible for Medicare, a government health agency said on Wednesday. Rising income levels, better employment rate and more people enrolling for Medicare,…

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 28
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences